Andrew Walker

Andrew Walker × Paul Cerro

Cerro’s HIMS thesis shifts attention from peptide launches to the data and labs layer: subscriber counts have “barely grown” for three quarters, making retention the lever for LTV and payback.The August 10 print will test Eucalyptus-driven revenue upside against lower EBITDA guidance, the first full Novo Nordisk partnership quarter, and execution by management Cerro says he does not trust.

Andrew Walker × Adam May

Maintenance data beat modeled scenarios, with clinical-remission deltas of 40% at 50mg and 39% at 25mg, versus Rinvoq’s 18% endoscopic remission.After seven cancers drove the stock below $100, May cites a pooled 0.59 rate versus 0.5 background, while Part 2’s 500–600 patients due before June ends may clarify safety; mid-2027 Crohn’s data and label risk remain catalysts.

Andrew Walker × Leo Trudel

Stevanato’s roughly 50% drawdown on oral GLP-1 fears contrasts with high-value solutions nearing half of revenue.Those solutions are growing 15-18% at roughly twice the gross margin of the rest, supporting a mix-shift case.Trudel says oral GLP-1s are about half as effective as injectables and models 18.6% EBITDA CAGR, while Walker flags non-take-or-pay capacity risk and ongoing headline sensitivity.

Andrew Walker × Andy Summers

Theravance’s accelerated strategic review follows a Phase 3 failure and is read by holders as a potential sale.Yupelri grew 12% to $260M, appears patent-protected to 2039, with zero R&D and sharply lower OpEx.Summers assigns a 90% chance of a deal before May 7–8 earnings, but generic timing and no-sale downside remain risks.

Andrew Walker × Adam May

Adam May pairs trial-outcome forecasting with a reason consensus is wrong, using Abivax’s maintenance-enrollment math and Nektar’s forensic reconstruction of Lilly’s rezpeg analysis to identify mispriced biotech data.Nektar’s durable response, four-times-yearly dosing and an OX40 vacuum support its asymmetric setup, while Abivax’s phase-three, hard-to-copy mechanism makes a potential buyout thesis; June maintenance data are the key catalyst, with May watching a 20–30% delta.

Andrew Walker × Dan Rasmussen × Greg Obenshain

Verdad’s systematic biotech strategy challenges traditional screens by targeting a sector representing 25% of the Russell 2000 and showing the market’s lowest correlation.Among 70 specialist funds, consensus ownership relative to total fund ownership outperforms lone-wolf ideas, while spend-based value is an even stronger return driver; diversified shorts may reduce volatility drag, but 13F lag and PIPE ownership data remain risks.

Andrew Walker × Judd Arnold

Judd Arnold’s process now favors liquid inflections where small “junior varsity positions” can become large once “people will care,” rather than merely cheap, illiquid stocks.His $TOI thesis is that capitated oncology can redirect prescribing toward lower-cost regimens, with Florida contracts at roughly $35 PMPM versus $3 in California, but clinician control, reimbursement capture, and the post-SPAC SG&A blowout remain execution risks.

Andrew Walker

Sage’s $8.50-per-share Supernus deal implies enterprise value below $200 million, potentially inviting a Biogen topping bid within one to two weeks.Keros returned $375 million against $720 million of first-quarter cash, while shareholder pressure may drive further distributions and cost cuts.American Place is outperforming Chamonix; refinancing without equity dilution remains Full House’s catalyst amid construction, overruns, and casino ramp-up risks.

Andrew Walker

Markets recovered from the roughly 10% “Liberation Day” drop, but delayed plants, stores, deals, and capital spending leave tariff policy and recession risk unresolved.AI may commoditize quantitative work and 10-K comparison, making judgment and real-time management assessment scarcer despite meetings that expose investors to elite salesmanship.Biotech optionality can vanish after 50% clinical odds, time discounting, trial costs, and roughly $50 million annual overhead when incentives favor continued spending.

Andrew Walker

KROS’s review lifted shares from roughly $10 to $12, yet they remain near 60% of Walker’s estimated $16-$18 net cash per share, plus Takeda royalties.Across pre-commercial biotech, liquidation or rationalization may unlock severely discounted cash, while fixed stock compensation can reach 15% annual dilution after a collapse, making governance and capital discipline key catalysts.